Nilotinib (AMN-107)

製品コードS1033

Nilotinib (AMN-107)化学構造

分子量(MW):529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 34860.00
JPY 78020.00
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明 Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
特性 A selective inhibitor of native and mutant Bcr-Abl.
ターゲット
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
体外試験

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1yLkCwNFE1PCEQvF2= M{LTUXNCVkeHUh?=
KU812 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y0NmlEPTB;MD6wNFI1QCEQvF2= M4DZOnNCVkeHUh?=
EM-2 M4noPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfkdXp5UUN3ME2wMlAxPDFizszN NHvVWYdUSU6JRWK=
LAMA-84 M{jB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjz[YJFUUN3ME2wMlAxPDlizszN MlXJV2FPT0WU
MEG-01 NGTQbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknBTWM2OD1yLkCwPFI5KM7:TR?= NWXjPVlNW0GQR1XS
BV-173 NIrDVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEGwPFkh|ryP NGC5NJdUSU6JRWK=
KASUMI-1 M4DW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXMTWM2OD1yLkCyOFE{KM7:TR?= NHPxZ|hUSU6JRWK=
NB7 M4S1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K3U2lEPTB;MD6xN|Q{QSEQvF2= MWrTRW5ITVJ?
BHT-101 NUL5N3dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDzPGRKSzVyPUCuOlQzPjNizszN NGD0cI1USU6JRWK=
CGTH-W-1 M{DjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrUR4IzUUN3ME2wMlY1QDdizszN MortV2FPT0WU
HMV-II MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjJPGZKSzVyPUCuO|Q5PzRizszN M4LEZ3NCVkeHUh?=
NKM-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfiWHhKSzVyPUCuPVAyPSEQvF2= NUjpZmx7W0GQR1XS
LB2241-RCC MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMEKyNlgh|ryP NU\5Z5dvW0GQR1XS
NCI-H1703 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13LdWlEPTB;MT6xPFg4KM7:TR?= NXnRdJY3W0GQR1XS
BE-13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT1eVBKSzVyPUGuNlc1OTZizszN M4C4W3NCVkeHUh?=
ACN NF\4cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrkZ2xSUUN3ME2xMlU2ODd5IN88US=> MVnTRW5ITVJ?
A204 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnKTWM2OD1zLkW3NlA2KM7:TR?= MljvV2FPT0WU
HOP-62 NF:xclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwOEKwO|ch|ryP NYTRXoVVW0GQR1XS
H9 NH\VSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7mUmpKSzVyPUKuO|M4QTNizszN MlzRV2FPT0WU
HCC1806 M3LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPHRWZKSzVyPUKuO|Q{OjdizszN MkLsV2FPT0WU
NOS-1 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XVO2lEPTB;Mj64O|ExOiEQvF2= Mk\tV2FPT0WU
RS4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\wTWM2OD1{LkmwOlI{KM7:TR?= M2PoV3NCVkeHUh?=
JAR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHVclZ[UUN3ME2yMlkzODh2IN88US=> NWH1O5NLW0GQR1XS
T98G MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImyWlhKSzVyPUOuNFE{OTNizszN MorLV2FPT0WU
NCI-SNU-1 NHuz[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwNECwPVIh|ryP MVLTRW5ITVJ?
SK-MEL-1 M4\GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;MUWlEPTB;Mz60N|AzQSEQvF2= NWrXW|h7W0GQR1XS
L-363 NHvJbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwNkGxNFch|ryP M3m1U3NCVkeHUh?=
SW982 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLFPVBKSzVyPUOuOlQyPjlizszN MnX6V2FPT0WU
HT-1080 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HoWmlEPTB;Mz65NVc4PSEQvF2= MYPTRW5ITVJ?
G-402 NI\qdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRwM{GyNFMh|ryP M4jWV3NCVkeHUh?=
HOS M2XXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\6TWM2OD12LkiwNlgzKM7:TR?= M1vSWHNCVkeHUh?=
SK-NEP-1 NIHlZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j4XGlEPTB;ND64N|E6OSEQvF2= M{DuRnNCVkeHUh?=
HAL-01 NUXP[pQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:4[5RKSzVyPUSuPFgzPDJizszN NH;5T41USU6JRWK=
SBC-1 NEP4WJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\nOGtRUUN3ME20MlkxQTB5IN88US=> MWPTRW5ITVJ?
CTV-1 NUe0OnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBb41uUUN3ME21MlQ5QTN6IN88US=> Moj2V2FPT0WU
LCLC-103H NHvjSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwN{e0O|Eh|ryP M3zvVnNCVkeHUh?=
RVH-421 NWHldZVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml32TWM2OD13Lke3OVM3KM7:TR?= NHy1OVFUSU6JRWK=
K-562 Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ofmVSUUN3ME21MlkxOzZizszN NWjyVXpuW0GQR1XS
CAL-33 NGnUPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljMTWM2OD14LkOxN|U6KM7:TR?= M2rQVnNCVkeHUh?=
MDA-MB-361 NVGwb2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTwU41KSzVyPU[uN|M3QTlizszN NFTkWXVUSU6JRWK=
IGROV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGbmlEPTB;Nj60O|E6OSEQvF2= MV;TRW5ITVJ?
NY NVS2foFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjxOHRkUUN3ME22MlU{PTl7IN88US=> NWXHc5R6W0GQR1XS
Ramos-2G6-4C10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZwNk[5N|Eh|ryP MYrTRW5ITVJ?
HuO9 M3zWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36xZ2lEPTB;Nj63N|k3PCEQvF2= NHHlSmxUSU6JRWK=
MS-1 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz6TWM2OD15LkGxPVU{KM7:TR?= MYLTRW5ITVJ?
RPMI-8226 NXrFdnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPW[nhKSzVyPUeuNlgzQDdizszN MmXWV2FPT0WU
HDLM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTdwNECxOFkh|ryP NIXxPGNUSU6JRWK=
D-566MG NELJemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXjWnFjUUN3ME23MlQ4OTV3IN88US=> NFzWTXFUSU6JRWK=
SK-MEL-24 M4nGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LsfWlEPTB;Nz62N|M6OiEQvF2= MVrTRW5ITVJ?
COLO-679 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTdwOUi2O|Eh|ryP MX;TRW5ITVJ?
EW-13 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4PWlEPTB;OD6zNlA2PCEQvF2= NIjLUm1USU6JRWK=
A388 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XDXGlEPTB;OD6zPFQ5OSEQvF2= NEjvdHhUSU6JRWK=
UM-UC-3 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHWTWM2OD16LkSzPVU3KM7:TR?= MnvVV2FPT0WU
NUGC-3 NGrDXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O0WmlEPTB;OD61N|U5OiEQvF2= MljEV2FPT0WU
COLO-668 NHLIUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLTTWM2OD16LkW5OFkyKM7:TR?= NFPFZpZUSU6JRWK=
MOLT-4 NHHGfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRThwNkKzOVMh|ryP MXfTRW5ITVJ?
D-423MG Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfkNmFnUUN3ME24Mlg{PzV4IN88US=> M1vQOXNCVkeHUh?=
CTB-1 M3TTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TsXmlEPTB;OD64O|EzQCEQvF2= NFXodGJUSU6JRWK=
BCPAP M1;JVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XmPGlEPTB;OT6wNlU3OiEQvF2= M4fwSHNCVkeHUh?=
GCT MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y4ZmlEPTB;OT6wPVg{OSEQvF2= NUK4cW1yW0GQR1XS
ACHN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml76TWM2OD17LkKzOlMzKM7:TR?= NFH2SXVUSU6JRWK=
KYSE-520 NV7JSZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTlwM{O0PFIh|ryP MXrTRW5ITVJ?
LB771-HNC Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXtRoxmUUN3ME25Mlc3PDl5IN88US=> MmXxV2FPT0WU
MLMA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiyTWM2OD1zMD6wNVMzKM7:TR?= Mk\EV2FPT0WU
HEC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;FdldGUUN3ME2xNE4zQDB2IN88US=> Mn\XV2FPT0WU
HL-60 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFyLk[4OVMh|ryP Mn\uV2FPT0WU
A101D NUTG[4hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLSVnJTUUN3ME2xNE45QTJ|IN88US=> NEnWRYlUSU6JRWK=
A2058 NFPoeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF24UVFKSzVyPUGwMlkzPDVizszN MkHTV2FPT0WU
KARPAS-45 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnKSlRKSzVyPUGxMlA3OzVizszN NYO4NmpXW0GQR1XS
697 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFzLkKxNFEh|ryP MYrTRW5ITVJ?
NCI-N87 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILHNHZKSzVyPUGxMlc4OzFizszN MnfEV2FPT0WU
DSH1 NIX1S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\xOllKSzVyPUGxMlc6PTNizszN MnXyV2FPT0WU
HLE MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf6bol3UUN3ME2xNU45QDN7IN88US=> NHS4fphUSU6JRWK=
NCI-H720 NIX2XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TrXmlEPTB;MUKuOlgxOSEQvF2= Mk[1V2FPT0WU
EW-3 NWHve|l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnPSoRKSzVyPUGyMlk{ODdizszN M1HFe3NCVkeHUh?=
AGS NGT6Z29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjDfVhJUUN3ME2xN{4xOzVzIN88US=> MUjTRW5ITVJ?
ES5 NEHMTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TLW2lEPTB;MUOuNFUyOiEQvF2= MVTTRW5ITVJ?
DB Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHYTWM2OD1zMz6zNlU3KM7:TR?= NVvPcGtQW0GQR1XS
A4-Fuk NFn2[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW1SIxoUUN3ME2xN{41OTB{IN88US=> MVXTRW5ITVJ?
A427 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7meGljUUN3ME2xN{41QTd{IN88US=> MlPOV2FPT0WU
MN-60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpTWM2OD1zMz61PFQ{KM7:TR?= MVnTRW5ITVJ?
HCC2218 NF;pRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki3TWM2OD1zMz61PFU3KM7:TR?= MWjTRW5ITVJ?
MV-4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF|LkixN|ch|ryP NWHafmNpW0GQR1XS
GI-1 NF\nfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHN[4hQUUN3ME2xOE4yOTh2IN88US=> M2nmfnNCVkeHUh?=
JVM-3 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHmN4RKUUN3ME2xOE4zPjV4IN88US=> NWK1Nmd6W0GQR1XS
NCI-H2029 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LmWGlEPTB;MUSuNlczPyEQvF2= NWfPTnpVW0GQR1XS
TE-12 NWqyV5l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLVS4lKSzVyPUG0MlYxPDZizszN NUDGPHdbW0GQR1XS
WM-115 M4\LXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf0TWM2OD1zNT61Olg{KM7:TR?= MnOxV2FPT0WU
BB65-RCC NHv3fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDKVFh5UUN3ME2xOk4xOjRzIN88US=> NGTkWIdUSU6JRWK=
NCI-H1693 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF4LkO4NFIh|ryP NIe2XJFUSU6JRWK=
KARPAS-299 NUXBWHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF4Lk[yNFMh|ryP NWXxSmhSW0GQR1XS
UACC-257 NWDiSXk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLYTWM2OD1zNz6wOVgzKM7:TR?= MkHnV2FPT0WU
RKO MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF5Lk[0N|Mh|ryP MUTTRW5ITVJ?
HT-29 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO0TWM2OD1zNz63PFg6KM7:TR?= M1npXnNCVkeHUh?=
ES7 M1ziRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTQfGNKSzVyPUG4MlEyOjJizszN MWLTRW5ITVJ?
DEL NW[xVpl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPd2lEPTB;MUiuN|E4OiEQvF2= NH74dWZUSU6JRWK=
BT-549 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSzbHI1UUN3ME2xPE41ODl{IN88US=> NFfUZVJUSU6JRWK=
NCI-H1755 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfLW2tWUUN3ME2xPE42PzJ|IN88US=> Mme0V2FPT0WU
HCE-T MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\5elh6UUN3ME2xPE45OzRzIN88US=> NYXpc3N2W0GQR1XS
LU-139 M4q5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD1zOT6wOFU5KM7:TR?= NFWyNJBUSU6JRWK=
ECC10 NInpPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPDU21pUUN3ME2xPU4zPDd3IN88US=> M1PtfXNCVkeHUh?=
769-P M2T6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXlOI5KSzVyPUG5MlY{OzVizszN MVPTRW5ITVJ?
BALL-1 M4XzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTxVoNtUUN3ME2xPU43Pzd3IN88US=> NX3z[HFCW0GQR1XS
LXF-289 M{\Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e5R2lEPTB;MUmuPFk4QSEQvF2= NELKO5VUSU6JRWK=
TYK-nu NHvSc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF7LkmzNVUh|ryP NX;6[GhwW0GQR1XS
NCI-H630 NY\DRWQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF7LkmzO|gh|ryP M{nk[nNCVkeHUh?=
EW-18 NGPvcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;VdVhVUUN3ME2yNE4{QDB{IN88US=> NYTD[YdNW0GQR1XS
KYSE-150 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJyLkewOFch|ryP NEL4O2NUSU6JRWK=
LOXIMVI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJyLke1PFYh|ryP NY\kVmR{W0GQR1XS
HuP-T3 M2TLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn6dm1tUUN3ME2yNU4xQDV{IN88US=> M2LTPXNCVkeHUh?=
MFE-280 NWXO[YdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD1{MT61Olc6KM7:TR?= MVfTRW5ITVJ?
SK-OV-3 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnznTWM2OD1{MT64OFA5KM7:TR?= M1rDTnNCVkeHUh?=
QIMR-WIL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfDSII1UUN3ME2yNk4xPDd6IN88US=> MYTTRW5ITVJ?
NCI-H69 NXjhUmRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\l[FRpUUN3ME2yNk41Ojl7IN88US=> NXm4dHlLW0GQR1XS
TE-5 M3;N[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRVGUxUUN3ME2yNk41QTZ3IN88US=> NWTFUZJqW0GQR1XS
NCI-H1993 NXvEdJJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX71UXhUUUN3ME2yNk41QTdzIN88US=> NILKNphUSU6JRWK=
NCI-H1092 M2LpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLDTWM2OD1{Mz6yPFQ{KM7:TR?= M{O1[XNCVkeHUh?=
RH-1 NWOzc2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPScYtKSzVyPUKzMlU{PTdizszN MYjTRW5ITVJ?
DBTRG-05MG NUPWWIpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPnZppKSzVyPUKzMlg1PzJizszN Mo\yV2FPT0WU
Mo-T NGnhXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rz[2lEPTB;MkOuPUDPxE1? MX;TRW5ITVJ?
HD-MY-Z NF\4NFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;hfIRKSzVyPUK0MlI{PjJizszN NV3HO5htW0GQR1XS
NCI-H2342 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\XbXhKSzVyPUK0MlY4PjdizszN NYrFWZFMW0GQR1XS
C32 M{XXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKbVRKSzVyPUK0Mlk2PzZizszN M3zLbHNCVkeHUh?=
HTC-C3 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH3bIhEUUN3ME2yOU4{PTd5IN88US=> NEjpdXRUSU6JRWK=
NCI-H358 NFWwbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO0S2JEUUN3ME2yOU4{QTR|IN88US=> Mn7pV2FPT0WU
CAL-85-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ3LkS1O|ch|ryP MYPTRW5ITVJ?
HT-1197 M1rN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorSTWM2OD1{NT61N|E6KM7:TR?= NGO2bWlUSU6JRWK=
A172 M1fSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\NdpFKSzVyPUK1MlcyOzZizszN M2fWcXNCVkeHUh?=
SW1573 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ3Lke3PFUh|ryP Mnn5V2FPT0WU
EW-24 NHnmOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O2cWlEPTB;MkWuPVYzKM7:TR?= MYnTRW5ITVJ?
SK-MEL-2 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXLTWM2OD1{Nj6wN|EzKM7:TR?= NGrRR2hUSU6JRWK=
LU-65 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPPTWM2OD1{Nj6wOFUzKM7:TR?= Ml3MV2FPT0WU
KMOE-2 M17MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT4R2hKSzVyPUK2MlA6OTVizszN NHXk[mJUSU6JRWK=
H-EMC-SS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D5WmlEPTB;Mk[uOFEyPCEQvF2= M3vp[XNCVkeHUh?=
H4 NEPkUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ4LkSyOFMh|ryP MYDTRW5ITVJ?
DU-4475 NXvvZWdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H6VmlEPTB;MkeuNVg4OiEQvF2= NWTBXVgxW0GQR1XS
HCT-116 NXvWW4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvwTWM2OD1{Nz60N|Q6KM7:TR?= NF;0NG5USU6JRWK=
MSTO-211H MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVToVYx{UUN3ME2yO{43OjV3IN88US=> MnjYV2FPT0WU
NCI-H292 M1LFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ5Lkm2NVch|ryP MXfTRW5ITVJ?
NCI-H446 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[xZWlEPTB;MkiuNlExPSEQvF2= MkHyV2FPT0WU
NCI-H2009 NE\PVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fVb2lEPTB;MkmuNVQ{OSEQvF2= M2X4S3NCVkeHUh?=
MHH-ES-1 NV;4XolYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjdI5KSzVyPUK5MlM3QDVizszN NX;V[lNFW0GQR1XS
TI-73 NU[xRlk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ7LkSwNFEh|ryP M2TjTHNCVkeHUh?=
NCI-H2228 NFvNS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmwOI9KSzVyPUK5MlQ2QCEQvF2= NFLuPYlUSU6JRWK=
MHH-PREB-1 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\SPHNKSzVyPUK5MlU2ODVizszN M4[xOnNCVkeHUh?=
ChaGo-K-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ7Lk[wPVch|ryP NHXkeoFUSU6JRWK=
KY821 NYfSW2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsN2lEPTB;MkmuOlQ{OyEQvF2= NFWxNW5USU6JRWK=
NCI-H209 NH3xSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvjdohKSzVyPUK5Mlg{PjZizszN NEfj[WFUSU6JRWK=
NBsusSR MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTNdIFKSzVyPUK5Mlk6ODRizszN M172SXNCVkeHUh?=
NCI-H1304 NIGyTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNyLkW3NVYh|ryP NETqeYhUSU6JRWK=
NB14 NX21V|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBc2lEPTB;M{GuNFQ1PiEQvF2= M3vubHNCVkeHUh?=
HCC1419 NFvwe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD1|MT6yOEDPxE1? NF\lfmpUSU6JRWK=
KG-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TUNmlEPTB;M{GuO|QzQSEQvF2= NU\PUHV4W0GQR1XS
A2780 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnhPXlKSzVyPUOxMlg{PThizszN MU\TRW5ITVJ?
NCI-H28 M3i4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvsd2xKSzVyPUOxMlk5PjFizszN M3HUenNCVkeHUh?=
C2BBe1 M4PGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPD[|RKSzVyPUOyMlI3OzRizszN MYTTRW5ITVJ?
VA-ES-BJ NGfMN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHwSFhjUUN3ME2zNk4{OSEQvF2= MUPTRW5ITVJ?
SBC-5 M2nmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj2bldKSzVyPUOyMlg2OTFizszN MV;TRW5ITVJ?
OVCAR-4 M1\OdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W5SWlEPTB;M{OuOFg1QCEQvF2= NHPXTnRUSU6JRWK=
COR-L88 NHTxUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN2LkC3OFEh|ryP MkOyV2FPT0WU
SW954 NWn2WYZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfxSGNXUUN3ME2zOE4xPzV{IN88US=> M17XbnNCVkeHUh?=
COLO-684 NYWwfVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LUOmlEPTB;M{SuN|QxPCEQvF2= MknBV2FPT0WU
HCC70 M2Sycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHETWM2OD1|ND65OVE1KM7:TR?= M{HUNnNCVkeHUh?=
NCI-H1770 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOxTWM2OD1|ND65OlEh|ryP Mk\OV2FPT0WU
NCI-H1666 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvIZ|lKSzVyPUO1MlgzPTNizszN M1K1OHNCVkeHUh?=
YH-13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfud2FKSzVyPUO1MlkzKM7:TR?= Mn7SV2FPT0WU
DJM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN4LkiwOFkh|ryP NVnzUJFkW0GQR1XS
KNS-62 M{X1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknTTWM2OD1|Nj65OFM5KM7:TR?= MmjTV2FPT0WU
SK-MEL-30 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN5Lki3N|ch|ryP MUPTRW5ITVJ?
SJRH30 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[1SVE5UUN3ME2zPE44OzRzIN88US=> MoCwV2FPT0WU
GP5d M4O0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi0UGpYUUN3ME2zPE45PjV|IN88US=> M1XvbnNCVkeHUh?=
SW1116 NIqwN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN7LkK4NFUh|ryP MUHTRW5ITVJ?
COLO-800 NYD1dVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S5[WlEPTB;M{muN|Y{QCEQvF2= MXrTRW5ITVJ?
RD MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN7LkWyOVgh|ryP NGrEZ4dUSU6JRWK=
NCI-SNU-5 M4W0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN7Lk[5NVYh|ryP MnvSV2FPT0WU
HuO-3N1 M1;je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLc4hbUUN3ME20NE4yODhizszN M4LOfXNCVkeHUh?=
SK-UT-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH1eZp3UUN3ME20NE42Pjd2IN88US=> NXr5[|FTW0GQR1XS
SK-MEL-3 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTRyLkW5N|Ih|ryP M1q2VHNCVkeHUh?=
SK-MEL-28 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRyLk[0N|Uh|ryP MWjTRW5ITVJ?
SCC-4 M3zHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPPTXhKSzVyPUSxMlIyOzdizszN MnjaV2FPT0WU
no-11 NWrxcYxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRzLkezOVQh|ryP Ml\0V2FPT0WU
HT-144 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfze|NVUUN3ME20Nk4xPTZ5IN88US=> MnPvV2FPT0WU
MFM-223 NIPIfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjVenFyUUN3ME20Nk41ODJizszN M3Ts[nNCVkeHUh?=
ONS-76 NUDNWGlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBOWlEPTB;NEKuPFAyQCEQvF2= NUfxNmRYW0GQR1XS
ES8 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLhRmxKSzVyPUSzMlM3QThizszN NE\lcoxUSU6JRWK=
T-24 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG1cZNKSzVyPUSzMlQ{PjlizszN NEnSRZFUSU6JRWK=
GAMG Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD4TWM2OD12Mz60OVE4KM7:TR?= MUDTRW5ITVJ?
LU-135 NGC4cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR2LkC5NlMh|ryP M33JT3NCVkeHUh?=
HCC1187 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7WSo04UUN3ME20OE45OjZ{IN88US=> MW\TRW5ITVJ?
TE-1 M1\N[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjJcpRKSzVyPUS1MlE3PTRizszN MX3TRW5ITVJ?
J-RT3-T3-5 NGX0O2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TSUWlEPTB;NEWuOFMyPSEQvF2= M{XTenNCVkeHUh?=
GI-ME-N NUnlTWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrBfZRKSzVyPUS1Mlg6PTJizszN NGTY[ohUSU6JRWK=
D-392MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR3LkmyOVYh|ryP NXnPTIh3W0GQR1XS
KALS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR4LkeyOVch|ryP Mn7GV2FPT0WU
MMAC-SF NFTlUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;tRnNKSzVyPUS2Mlk6PTJizszN MXrTRW5ITVJ?
HSC-3 NUjxN2lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR5LkO2NFgh|ryP MVXTRW5ITVJ?
KM-H2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\qT2lEPTB;NEeuOlAxPyEQvF2= NGnnZndUSU6JRWK=
LoVo NHT6WGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTR6LkGwNFIh|ryP MnuxV2FPT0WU
NCI-H510A NUflU4V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KfmlEPTB;NEiuNVg4OSEQvF2= Mn7pV2FPT0WU
EW-11 NFPF[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPJTGJKSzVyPUS4MlI{PDhizszN MVrTRW5ITVJ?
HCC2998 NGPoSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfoSVNoUUN3ME20PE43OjN4IN88US=> M1T6cXNCVkeHUh?=
J82 NI\qNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfifYtnUUN3ME20PE44OjR{IN88US=> NEnjeJdUSU6JRWK=
ML-2 NF34XVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnDfmZoUUN3ME20PU41PjB3IN88US=> MY\TRW5ITVJ?
NCI-H2030 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzyW3ZnUUN3ME20PU44OTF5IN88US=> NWDSb414W0GQR1XS
NCI-H1792 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTR7Lki1NVgh|ryP MV\TRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

お薦めの試験操作(参考用のみ)

細胞試験: [4]
+ 展開
  • 細胞株: Human primary Schwann and schwannoma cells
  • 濃度: 1-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (参考用のみ)
動物試験:[6]
+ 展開
  • 動物モデル: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • 製剤: 10% NMP-90% PEG300, PEG300
  • 投薬量: 75 mg/kg, 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 529.52
化学式

C28H22F3N7O

CAS No. 641571-10-0
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03874858 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT03874858 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • 回答:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品

Tags: Nilotinib (AMN-107)を買う | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107)供給者 | Nilotinib (AMN-107)を購入する | Nilotinib (AMN-107)費用 | Nilotinib (AMN-107)生産者 | オーダーNilotinib (AMN-107) | Nilotinib (AMN-107)化学構造 | Nilotinib (AMN-107)分子量 | Nilotinib (AMN-107)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID